Novel Glutamatergic Treatments for Severe Mood Disorders

Current Behavioral Neuroscience Reports

Volumn 2, Issue 4, 2015, Pages 198-208

  Park, Minkyung ^a   Niciu, Mark J ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Glutamate; Metabotropic positive allosteric modulator; Mood disorders; N methyl d aspartate (NMDA) antagonist; Negative allosteric modulator

Indexed keywords

EID: 84994859480     PISSN: None     EISSN: 21962979     Source Type: Journal    
DOI: 10.1007/s40473-015-0050-5     Document Type: Review

References (91)

1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79. DOI: 10.1016/j.euroneuro.2011.07.018
2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–105. DOI: 10.1001/jama.289.23.3095
3. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, et al. Grand challenges in global mental health. Nature. 2011;475(7354):27–30. DOI: 10.1038/475027a
4. Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 2008;42(9):751–62. DOI: 10.1080/00048670802277206
5. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185(1):1–10. DOI: 10.1016/0014-2999(90)90204-J
6. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4. DOI: 10.1016/S0006-3223(99)00230-9
7. Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64. DOI: 10.1001/archpsyc.63.8.856
8. Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav. 2012;100(4):656–64. DOI: 10.1016/j.pbb.2011.08.008
9. Pilc A, Wieronska JM, Skolnick P. Glutamate-based antidepressants: preclinical psychopharmacology. Biol Psychiatry. 2013;73(12):1125–32. The article concisely summarizes glutamate-based antidepressants in pre-clinical studies and focuses on major concepts and mechanisms.
10. Monteggia LM, Zarate Jr C. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol. 2015;30:139–43. DOI: 10.1016/j.conb.2014.12.004
11. Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6(3):97–114. DOI: 10.1177/2040622315579059
12. Ohgi Y, Futamura T, Hashimoto K. Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med. 2015;15(3):206–21. DOI: 10.2174/1566524015666150330143008
13. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69(8):754–61. DOI: 10.1016/j.biopsych.2010.12.015
14. Duman RS, Aghajanian GK. Neurobiology of rapid acting antidepressants: role of BDNF and GSK-3beta. Neuropsychopharmacology. 2014;39(1):233. DOI: 10.1038/npp.2013.217
15. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res. 2005;136(1–2):29–37. DOI: 10.1016/j.molbrainres.2004.12.020
16. Gottmann K, Mittmann T, Lessmann V. BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. Exp Brain Res. 2009;199(3–4):203–34. DOI: 10.1007/s00221-009-1994-z
17. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–42. This is the largest clinical trial of ketamine to date. It validated the antidepressant effects of ketamine and used an active placebo, midazolam.
18. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–6. This is the largest trial of repeated ketamine infusion.
19. Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805–13. DOI: 10.1017/S1461145714001011
20. Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27(5):444–50. DOI: 10.1177/0269881113478283
21. Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28(6):536–44. DOI: 10.1177/0269881114527361
22. Lai R, Katalinic N, Glue P, Somogyi AA, Mitchell PB, Leyden J, et al. Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry. 2014;15(7):579–84. DOI: 10.3109/15622975.2014.922697
23. Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970–6. This is the first controlled study of intranasal ketamine.
24. Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 2012;169(8):868–9. DOI: 10.1176/appi.ajp.2012.12020219
25. Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013;16(9):2111–7. This is the first clinical trial to report the robust and rapid antidepressant effect of sublingual ketamine.
26. Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med. 2010;13(7):903–8. DOI: 10.1089/jpm.2010.9808
27. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry. 2010;43(1):33–5. DOI: 10.1055/s-0029-1237375
28. Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013;16(8):958–65. DOI: 10.1089/jpm.2012.0617
29. De Gioannis A, De Leo D. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Aust N Z J Psychiatry. 2014;48(7):686. DOI: 10.1177/0004867414520754
30. Glue P, Gulati A, Le Nedelec M, Duffull S. Dose- and exposure-response to ketamine in depression. Biol Psychiatry. 2011;70(4):e9–10. author reply e11-2. DOI: 10.1016/j.biopsych.2010.11.031
31. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology. 2010;113(3):678–84.
32. Nagele P, Duma A, et al. Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial. Soc Biol Psychiatry. 2015. This study showed that nitrous oxide, a non-ketamine NMDA receptor antagonist, had rapid antidepressant effects. This finding implicates NMDA receptor antagonism in the mechanism of antidepressant activity.
33. Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008;109(4):707–22. DOI: 10.1097/ALN.0b013e3181870a17
34. Lee SY, Chen SL, Chang YH, Chen SH, Chu CH, Huang SY, et al. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Affect Disord. 2012;138(3):295–300. DOI: 10.1016/j.jad.2012.01.024
35. Church J, Sawyer D, McLarnon JG. Interactions of dextromethorphan with the N-methyl-D-aspartate receptor-channel complex: single channel recordings. Brain Res. 1994;666(2):189–94. DOI: 10.1016/0006-8993(94)90771-4
36. Kelly TF, Lieberman DZ. The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. J Affect Disord. 2014;167:333–5. DOI: 10.1016/j.jad.2014.05.050
37. Zarate Jr CA, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153–5. DOI: 10.1176/appi.ajp.163.1.153
38. Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(10):966–73. DOI: 10.4088/JCP.12m08252
39. Serra G, Koukopoulos A, De Chiara L, Koukopoulos AE, Tondo L, Girardi P, et al. Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder. J Clin Psychiatry. 2015;76(1):e91–7. This article suggests that although memantine may not be an effective augmenting agent for major depressive disorder, it may be effective in bipolar depression.
40. Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A. 2014;111(23):8649–54. DOI: 10.1073/pnas.1323920111
41. Zarate Jr CA, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry. 2013;74(4):257–64. DOI: 10.1016/j.biopsych.2012.10.019
42. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19(9):978–85. DOI: 10.1038/mp.2013.130
43. Sanacora G, Johnson M, Khan A, Atkinson S, Riesenberg R, Schronen J. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: primary results from a randomized, placebo-controlled study (PURSUIT). 53rd Meeting of the ACNP. 2014. Hollywood, FL, USA.
44. Gielen M, Siegler RB, Mony L, Johnson JW, Paoletti P. Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature. 2009;459(7247):703–7. DOI: 10.1038/nature07993
45. Furukawa H, Singh SK, Mancusso R, Gouaux E. Subunit arrangement and function in NMDA receptors. Nature. 2005;438(7065):185–92. DOI: 10.1038/nature04089
46. Yao Y, Mayer ML. Characterization of a soluble ligand binding domain of the NMDA receptor regulatory subunit NR3A. J Neurosci. 2006;26(17):4559–66. DOI: 10.1523/JNEUROSCI.0560-06.2006
47. Miller OH, Yang L, Wang CC, Hargroder EA, Zhang Y, Delpire E, et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife. 2014;3:e03581.
48. Zhang C, Li Z, Wu Z, Chen J, Wang Z, Peng D, et al. A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacology (Berl). 2014;231(4):685–93. DOI: 10.1007/s00213-013-3297-0
49. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28(6):631–7. DOI: 10.1097/JCP.0b013e31818a6cea
50. Nicholson KL, Mansbach RS, Menniti FS, Balster RL. The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys. Behav Pharmacol. 2007;18(8):731–43. DOI: 10.1097/FBP.0b013e3282f14ed6
51. Ibrahim L, Diaz GN, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring WJ, et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32(4):551–7. DOI: 10.1097/JCP.0b013e31825d70d6
52. Millan MJ. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurol Disord. 2002;1(2):191–213. DOI: 10.2174/1568007024606258
53. Heresco-Levy U, Javitt DC, Gelfin Y, Gorelik E, Bar M, Blanaru M, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord. 2006;93(1–3):239–43. DOI: 10.1016/j.jad.2006.03.004
54. Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol. 2013;16(3):501–6. DOI: 10.1017/S1461145712000910
55. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol. 2004;7(1):1–8. DOI: 10.1017/S1461145703003900
56. Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 2014;23(2):243–54. This article provides a quick overview of GLYX-13, including its mechanism of action, preclinical results, and clinical data.
57. Naurex Inc. NRX-1074. 2015. http://www.naurex.com/pipeline/nrx-1074.
58. Browne CA, Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol. 2013;4:161. DOI: 10.3389/fphar.2013.00161
59. Maeng S, Zarate Jr CA, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349–52. DOI: 10.1016/j.biopsych.2007.05.028
60. Andreasen JT, Gynther M, Rygaard A, Bogelund T, Nielsen SD, Clausen RP, et al. Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests. Neurosci Lett. 2013;546:6–10. DOI: 10.1016/j.neulet.2013.04.045
61. Koike H, Chaki S. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res. 2014;271:111–5. DOI: 10.1016/j.bbr.2014.05.065
62. O’Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson’s disease. Curr Drug Targets. 2007;8(5):603–20. DOI: 10.2174/138945007780618517
63. Bleakman D, Alt A, Witkin JM. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets. 2007;6(2):117–26. DOI: 10.2174/187152707780363258
64. Ward SE, Bax BD, Harries M. Challenges for and current status of research into positive modulators of AMPA receptors. Br J Pharmacol. 2010;160(2):181–90. DOI: 10.1111/j.1476-5381.2010.00726.x
65. Nations KR, Bursi R, Dogterom P, Ereshefsky L, Gertsik L, Mant T, et al. Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection. Drugs R D. 2012;12(3):127–39. DOI: 10.2165/11634360-000000000-00000
66. Rondard P, Pin JP. Dynamics and modulation of metabotropic glutamate receptors. Curr Opin Pharmacol. 2015;20:95–101. DOI: 10.1016/j.coph.2014.12.001
67. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron. 1999;23(3):583–92. DOI: 10.1016/S0896-6273(00)80810-7
68. Alagarsamy S, Marino MJ, Rouse ST, Gereau RW, Heinemann SF, Conn PJ. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci. 1999;2(3):234–40. DOI: 10.1038/6338
69. Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A, et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry. 2011;168(7):727–34. DOI: 10.1176/appi.ajp.2011.09111607
70. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A. 2007;104(39):15537–42. DOI: 10.1073/pnas.0707484104
71. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132(7):1423–30. DOI: 10.1038/sj.bjp.0703923
72. Liu CY, Jiang XX, Zhu YH, Wei DN. Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: role of brain-derived neurotrophic factor. Neuroscience. 2012;223:219–24. DOI: 10.1016/j.neuroscience.2012.08.010
73. Legutko B, Szewczyk B, Pomierny-Chamiolo L, Nowak G, Pilc A. Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacol Rep. 2006;58(3):427–30.
74. Palucha A, Branski P, Szewczyk B, Wieronska JM, Klak K, Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav. 2005;81(4):901–6. DOI: 10.1016/j.pbb.2005.06.015
75. Pomierny-Chamiolo L, Poleszak E, Pilc A, Nowak G. NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacol Rep. 2010;62(6):1186–90. DOI: 10.1016/S1734-1140(10)70381-9
76. Domin H, Szewczyk B, Wozniak M, Wawrzak-Wlecial A, Smialowska M. Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression. Behav Brain Res. 2014;273:23–33. DOI: 10.1016/j.bbr.2014.07.019
77. Quiroz J, Tamburri P, Deptula D, Banken L, Beyer U, Fontoura P, et al. The efficacy and safety of basimglurant as adjunctive therapy in major depression: a randomized, double-blind, placebo-controlled study. Neuropsychopharmacology. 2014;39:S376–7. This article discusses the difficulties associated with clinical trials when placebo rates are high and explores possible solutions.
78. Stolk P, Ten Berg MJ, Hemels ME, Einarson TR. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother. 2003;37(12):1891–9. DOI: 10.1345/aph.1D172
79. Tamaru Y, Nomura S, Mizuno N, Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience. 2001;106(3):481–503. DOI: 10.1016/S0306-4522(01)00305-0
80. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology. 2004;46(4):457–67. DOI: 10.1016/j.neuropharm.2003.10.009
81. Dwyer JM, Lepack AE, Duman RS. mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade. Int J Neuropsychopharmacol. 2012;15(4):429–34. DOI: 10.1017/S1461145711001702
82. Campo B, Kalinichev M, Lambeng N, El Yacoubi M, Royer-Urios I, Schneider M, et al. Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet. 2011;25(4):152–66. DOI: 10.3109/01677063.2011.627485
83. Goeldner C, Ballard TM, Knoflach F, Wichmann J, Gatti S, Umbricht D. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology. 2013;64:337–46. DOI: 10.1016/j.neuropharm.2012.08.001
84. Bradley SR, Levey AI, Hersch SM, Conn PJ. Immunocytochemical localization of group III metabotropic glutamate receptors in the hippocampus with subtype-specific antibodies. J Neurosci. 1996;16(6):2044–56.
85. Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, van Der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci. 2003;17(11):2409–17. DOI: 10.1046/j.1460-9568.2003.02667.x
86. O’Mahony CM, Bravo JA, Dinan TG, Cryan JF. Comparison of hippocampal metabotropic glutamate receptor 7 (mGlu7) mRNA levels in two animal models of depression. Neurosci Lett. 2010;482(2):137–41. DOI: 10.1016/j.neulet.2010.07.018
87. Bradley SR, Uslaner JM, Flick RB, Lee A, Groover KM, Hutson PH. The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling. Pharmacol Biochem Behav. 2012;101(1):35–40. DOI: 10.1016/j.pbb.2011.11.006
88. Palucha-Poniewiera A, Szewczyk B, Pilc A. Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology. 2014;82:59–68. DOI: 10.1016/j.neuropharm.2014.03.001
89. Sukoff Rizzo SJ, Leonard SK, Gilbert A, Dollings P, Smith DL, Zhang MY, et al. The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther. 2011;338(1):345–52. DOI: 10.1124/jpet.110.177378
90. Palucha-Poniewiera A, Branski P, Lenda T, Pilc A. The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N′-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent. J Pharmacol Exp Ther. 2010;334(3):1066–74. DOI: 10.1124/jpet.110.169730
91. Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015;40(2):259–67. DOI: 10.1038/npp.2014.261